Kyntra Bio, Inc.
KYNBNASDAQHealthcareBiotechnology
Previous close
$7.52
+$0.20 · +2.73%
KYNB company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
76
Undervalued
Momentum
47
Neutral
Sentiment
48
Mixed
Risk resilience
45
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteKyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Thane Wettig
- Listed since
- Nov 14, 2014
- Employees
- 34
Market position
Day range
Current $7.52
52-week range
Current $7.52
- Open
- $7.41
- Previous close
- $7.32
- Volume
- 40.01K
- 2.55× average
- Average volume
- 15.67K
- Average daily volume
- Market cap
- 30.44M USD
- Beta
- 1.04
- Market reference 1
- 50-day average
- $7.1186
- +5.64% above average
- 200-day average
- $7.6811
- -2.10% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 73.17M USD
- P/E (TTM)
- 0.13×
- P/B (TTM)
- -1.01×
- P/S (TTM)
- 6.59×
- EV / EBITDA
- -1.27×
- Earnings yield
- 516.80%
- Free cash flow yield
- -13.56%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 18.15%
- Operating margin
- -1101.02%
- Net margin
- 3967.77%
- Return on equity
- -610.73%
- Return on assets
- 153.40%
- Return on invested capital
- -50.72%
Financial health
- Debt / equity
- 0×
- Current ratio
- 3.39×
KYNB peers
ETFs holding KYNB
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research KYNBresearch.disclaimer